[1] 王卫星. 89SrCl2联合唑来膦酸治疗前列腺癌骨转移[J].四川医学, 2012, 33(12):2158-2159. DOI:10.3969/j.issn.1004-0501.2012. 12.055.
Wang WX. Combined therapy of 89Sr-chloride and zoledronic acid in prostate cancer patients with bone metastases[J]. Sichuan Med J, 2012, 33(12):2158-2159.  doi: 10.3969/j.issn.1004-0501.2012.12.055
[2] Carlin BI, Andriole GL. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma[J]. Cancer, 2000, 88(12 Suppl):S2989-2994. DOI:10.1002/1097-0142(20000615)88:12+<2989:AID-CNCR14>3.0.CO;2-Q.
[3] Keller ET, Brown J. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity[J]. J Cell Biol, 2004, 91(4):718-729. DOI:10.1002/jcb.10662.
[4] Clark JC, Dass CR, Choong PF. Current and future treatments of bone metastases[J]. Expert Opin Emerg Drugs, 2008, 13(4):609-627. DOI:10.1517/14728210802584217.
[5] Facchini G, Caraglia M, Santini D, et al. The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events(SRE)[J]. J Exp Clin Cancer Res, 2007, 26(3):307-312.
[6] Fitch M, Maxwell C, Ryan C, et al. Bone metastases from advanced cancers:clinical implications and treatment options[J]. Clin J Oncol Nurs, 2009, 13(6):701-710. DOI:10.1188/09.CJON.701-710.
[7]

石远凯.肺癌诊断治疗学[M].北京:人民卫生出版社, 2008:381-382.

Shi YK. Diagnosis and treatment of lung cancer[M]. Beijing:People's Medical Press, 2008:381-382.

[8] Storto G, Klain M, Paone G, et al. Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases[J]. Bone, 2006, 39(1):35-41. DOI:10.1016/j.bone.2005.12.004.
[9]

Kamba T, Kamoto T, Maruo S, et al. A phase Ⅲ multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease:results of the ZAPCA trial[J/OL]. Int J Clin Oncol, 2017, 22(1):166-173[2016-12-16]. https://link.springer.com/article/10.1007%2Fs10147-016-1037-2. DOI:10.1007/s10147-016-1037-2.

[10] Soloway MS, Hardeman SW, Hickey D, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan[J]. Cancer, 1988, 61(1):195-202. DOI:10.1002/1097-0142(19880101)61:1<195:AID-CNCR2820610133>3.0.CO;2-Y.
[11] Kotake T, Usami M, Akaza H, et al. Goserelin acetate with or without antiandrogen or estrogen in the treatment of patients with advanced prostate cancer:a multicenter, randomized, controlled trial in Japan[J]. Jpn J Clin Oncol, 1999, 29(11):562-570. DOI:10. 1093/jjco/29.11.562.
[12] Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer[J]. N Engl J Med, 1998, 339(15):1036-1042. DOI:10.1056/NEJM199810083391504.
[13] Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam:a double-blind placebo-controlled clinical trial[J]. J Clin Oncol, 1998, 16(4):1574-1581. DOI:10.1200/JCO. 1998.16.4.1574.
[14] 白永利, 王林, 董莉.唑来膦酸钠联合89SrCl2治疗骨转移瘤的临床疗效[J].现代肿瘤医学, 2016, 24(5):815-818. DOI:10.3969/j.issn.1672-4992. 2016.05.039.
Bai YL, Wang L, Dong L. Clinical observation of zoledronic acid combined with 89SrCl2 in the treatment of bone metastasis tumor[J]. Modern Oncol, 2016, 24(5):815-818.  doi: 10.3969/j.issn.1672-4992.2016.05.039
[15] Body JJ. Bone metastases and tumor-induced hypercalcemia[J]. Curr Opin Oncol, 1992, 4(4):624-631. DOI:10.1097/00001622-199208000-00005.
[16] Hortobagyi GN. Novel approaches to the management of bone metastases in patients with breast cancer[J]. Semin Oncol, 2002, 29(3 Suppl 11):S134-144. DOI:10.1016/S0093-7754(02)70137-1.
[17] 蒙荣钦, 李昌林, 朱云芝, 等.唑来膦酸联合89Sr治疗恶性肿瘤晚期多发骨转移疗效观察[J].中华实用诊断与治疗杂志, 2013, 27(3):277-278.
Meng RQ, Li CL, Zhu YZ, et al. Clinical observation of zoledronic acid combined with 89SrCl2 in the treatment of multiple bone metastases tumor[J]. J Chin Pract Diagn Ther, 2013, 27(3):277-278.
[18] Yamada K, Yoshimura M, Kaise H, et al. Concurrent use of Sr-89 chloride with zoledronic acid is safe and effective for breast cancer patients with painful bone metastases[J]. Exp Ther Med, 2012, 3(2):226-230. DOI:10.3892/etm.2011.405.